Diagnosis and screening currently too complex and expensive, but new options emerging.
20 January 2015 | UNITAID press release
The NHS is to delay the introduction of a highly expensive drug that can save the lives of people infected with the hepatitis C virus. The move by NHS England is unprecedented, because the NHS rationing body, Nice (the National Institute for Health and Care Excellence) has approved the drug. Nice says sofosbuvir is cost-effective, because it is a cure for people who would otherwise run up huge NHS bills.
16 January 2015 | The Guardian
Thousands of people, diagnosed with hepatitis C, have rallied in several cities across Spain to urge the government to make it easier for patients with this disease to access the latest-generation medicines.
12 January 2015 | Press TV
A 24-week course of sofosbuvir and ribavirin can eliminate hepatitis C virus infection in two-thirds of patients who undergo liver transplantation, with positive consequences on their short- and long-term prognoses, according to two new studies published in Gastroenterology, the official journal of the American Gastroenterological Association.
09 January 2015 | Eurekalert Inf Dis
Increasing evidence suggests that hepatitis C transmits sexually among HIV-negative men who have sex with men, and not just among HIV-positive MSM.
26 December 2014 | AIDSMeds
Cigna is monitoring the health outcomes of customers with hepatitis C who have undergone treatment using a prescription combination with the drug Sovaldi. Cigna found that 91.1% of customers achieved a sustained virologic response (SVR). Customers who have an SVR when tested 12 weeks after the completion of treatment are considered cured.
17 December 2014 | Insurance News Net
Gilead has been selling a twelve week regimen of Sovaldi in the United States for approximately $84,000, or $1,000 per pill. This is significantly more than the original price projection for Sovaldi, and in sharp contrast to the prices at which the drug is being made available in other countries. Gilead recently announced its intention to make Sovaldi available in 91 developing countries at deeply discounted prices, and the drug is reportedly available in Egypt for 99% below the U.S. price. This obvious pricing paradox is under investigation by the Senate Finance Committee, which has questioned if the market for Sovaldi “is working efficiently and rationally,” and whether “payors of health care….can carry such a load.”
12 December 2014 | Chimicles & Tikellis press release
Lax oversight of blood banks means about a fifth of patients in Pakistan who get regular transfusions have been infected with hepatitis, a top government health official said on Friday. Some also get HIV.
09 December 2014 | HepatitisCNewDrugs
Clinical trials for some of the new direct-acting agents against hepatitis C (HCV) have yielded some impressive efficacy numbers. But how well do the drugs stack up in the real world?
11 November 2014 | MedPage Today
Daclatasvir is an oral once-daily pill, used in combination with other medicinal products, to treat adult patients with chronic hepatitis C. The decision makes Scotland the first country in Europe to adopt positive guidance for daclatasvir and means it will be routinely available to eligible patients through the Scottish NHS.
11 November 2014 | STV